Annual Working Capital
$10.77 M
-$9.90 M-47.90%
December 31, 2023
Summary
- As of February 7, 2025, IKT annual working capital is $10.77 million, with the most recent change of -$9.90 million (-47.90%) on December 31, 2023.
- During the last 3 years, IKT annual working capital has risen by +$711.60 thousand (+7.07%).
- IKT annual working capital is now -71.96% below its all-time high of $38.42 million, reached on December 31, 2021.
Performance
IKT Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
-$717.40 K
-$5.62 M-114.65%
September 30, 2024
Summary
- As of February 7, 2025, IKT quarterly working capital is -$717.40 thousand, with the most recent change of -$5.62 million (-114.65%) on September 30, 2024.
- Over the past year, IKT quarterly working capital has dropped by -$5.62 million (-114.65%).
- IKT quarterly working capital is now -101.52% below its all-time high of $47.30 million, reached on June 30, 2021.
Performance
IKT Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
IKT Working Capital Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -47.9% | -114.7% |
3 y3 years | +7.1% | -102.9% |
5 y5 years | +554.0% | -102.9% |
IKT Working Capital Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -72.0% | at low | -101.9% | at low |
5 y | 5-year | -72.0% | +355.4% | -101.5% | +87.8% |
alltime | all time | -72.0% | +355.4% | -101.5% | +87.8% |
Inhibikase Therapeutics Working Capital History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | -$717.40 K(-114.6%) |
Jun 2024 | - | $4.90 M(-25.5%) |
Mar 2024 | - | $6.57 M(-39.0%) |
Dec 2023 | $10.77 M(-47.9%) | $10.77 M(-27.3%) |
Sep 2023 | - | $14.81 M(-23.1%) |
Jun 2023 | - | $19.25 M(-22.9%) |
Mar 2023 | - | $24.96 M(+20.7%) |
Dec 2022 | $20.68 M | $20.68 M(-16.5%) |
Sep 2022 | - | $24.77 M(-15.9%) |
Jun 2022 | - | $29.46 M(-13.4%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2022 | - | $34.01 M(-11.5%) |
Dec 2021 | $38.42 M(+281.8%) | $38.42 M(-11.0%) |
Sep 2021 | - | $43.16 M(-8.8%) |
Jun 2021 | - | $47.30 M(+471.1%) |
Mar 2021 | - | $8.28 M(-17.7%) |
Dec 2020 | $10.06 M(-338.5%) | $10.06 M(-271.0%) |
Sep 2020 | - | -$5.88 M(+29.6%) |
Jun 2020 | - | -$4.54 M(+3.2%) |
Mar 2020 | - | -$4.40 M(+4.3%) |
Dec 2019 | -$4.22 M(+77.7%) | -$4.22 M |
Dec 2018 | -$2.37 M | - |
FAQ
- What is Inhibikase Therapeutics annual working capital?
- What is the all time high annual working capital for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual working capital year-on-year change?
- What is Inhibikase Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly working capital year-on-year change?
What is Inhibikase Therapeutics annual working capital?
The current annual working capital of IKT is $10.77 M
What is the all time high annual working capital for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual working capital is $38.42 M
What is Inhibikase Therapeutics annual working capital year-on-year change?
Over the past year, IKT annual working capital has changed by -$9.90 M (-47.90%)
What is Inhibikase Therapeutics quarterly working capital?
The current quarterly working capital of IKT is -$717.40 K
What is the all time high quarterly working capital for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly working capital is $47.30 M
What is Inhibikase Therapeutics quarterly working capital year-on-year change?
Over the past year, IKT quarterly working capital has changed by -$5.62 M (-114.65%)